Skip to main content
Psychedex

MDAI

5,6-methylenedioxy-2-aminoindane

1Provenance card

the boundary, as counts

Sources

1913 with DOI

1 strong · 10 moderate · 8 weak

Compilations

12026-05-03T17:48:38.853Z

pipeline-v5 · prompt hash not recorded — run predates 2026-09

Decisions

31last ruled 2026-06-04

0 awaiting a ruling

Issued documents

42026-10-19T20:32:38.230Z

notice · info card · emergency

Searches

152 with no results

queries and counts on the build

Claims checked

9056 supported

56 supported · 34 not

Correspondence

0received

consent field ships in Phase 4

Edges

258

derivations recorded for this entity

Complete over 19 sources, 1 compilation, and 31 decisions.Not here: the private journal (never).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/mdai/archive

Timeline

what happened, newest first — claims, searches and artifacts stay inside Build

  1. 2026-10-19issueIssued info_card
  2. 2026-10-02srcAcute psychotropic, autonomic, and endocrine effects of 5,6-methylenedioxy-2-aminoindane (MDAI) compared with 3,4-methylenedioxymethamphetamine (MDMA) in human volunteers: A self-administration study.
  3. 2026-10-02src5,6-Methylenedioxy-2-aminoindane: from laboratory curiosity to 'legal high'.
  4. 2026-10-02srcMDAI (5,6-methylenedioxy-2-aminoindane; 6,7-dihydro-5H-cyclopenta[f][1,3]benzodioxol-6-amine; 'sparkle'; 'mindy') toxicity: a brief overview and update.
  5. 2026-10-02srcPharmacological profiles of aminoindanes, piperazines, and pipradrol derivatives.
  6. 2026-10-02srcPostmortem distribution and redistribution of MDAI and 2-MAPB in blood and alternative matrices
  7. 2026-10-02srcDeath following consumption of MDAI and 5-EAPB
  8. 2026-10-02srcMulticomponent LC-MS/MS screening method for detection of new psychoactive drugs, legal highs, in urine-experience from the Swedish population.
  9. 2026-10-02srcEmerging toxicity of 5,6-methylenedioxy-2-aminoindane (MDAI): Pharmacokinetics, behaviour, thermoregulation and LD50 in rats.
  10. 2026-10-02srcCytotoxicity of new psychoactive substances and other drugs of abuse studied in human HepG2 cells using an adopted high content screening assay.
  11. 2026-10-02srcLocomotor, discriminative stimulus, and place conditioning effects of MDAI in rodents.
  12. 2026-10-02srcStructure-Activity Relationships of Substituted Cathinones, with Transporter Binding, Uptake, and Release
  13. 2026-10-02srcCentral cyanosis on a psychiatric unit treated at the Salford Royal Hospital.
  14. 2026-10-02srcSynthetic Aminoindanes: A Summary of Existing Knowledge.
  15. 2026-10-02src5-Iodo-2-aminoindan, a nonneurotoxic analogue of p-iodoamphetamine.
  16. 2026-10-02srcNonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA).
  17. 2026-10-02srcSWGDRUG Monograph: 5,6-MDAI
  18. 2026-10-02srcMDAI Law
  19. 2026-10-02srcMDAI Legal Status
  20. 2026-10-02srcAminoindanes (UNODC Substance Group Details)
  21. 2026-09-04issueIssued emergency
  22. 2026-09-04issueIssued info_card
  23. 2026-09-04issueIssued notice
  24. 2026-06-04proposal29 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
  25. 2026-06-04publicationPublication — backfill
  26. 2026-05-03revisionRevision 1
  27. 2026-05-03absenceSearched ClinicalTrials.gov for "MDAI aminoindane" — no results
  28. 2026-05-03absenceSearched ClinicalTrials.gov for "MDAI aminoindane" — no results
  29. 2026-05-03genGeneration — pipeline-v5pipeline-v5
  30. 2026-05-03rungeneration run

The same entries, as forms: six forms.